论文部分内容阅读
２０例轻、中度发作的支气管哮喘患者服用优喘平４００ｍｇ／ｄ共１４ｄ，记录临床症状及早、晚ＰＥＦＲ，用药前后测ＦＥＶ１，服药后第１４ｄ作血浆茶硷浓度峰、谷值测定并进行统计学处理。发现用药后临床症状与肺功能（ＦＥＶ１、ＰＥＦＲ）显著改善（Ｐ＜０．００１），血浆茶硷浓度为５．２４～１１．８７μｇ／ｍｌ。表明轻、中度发作的哮喘患者口服优喘平４００ｍｇ／ｄ，可达一个低而稳定的血药浓度范围，临床效果良好，除少许胃肠道刺激症状外，基本上无毒副作用。作者认为优喘平是一个安全而有效的抗哮喘药物。
Twenty patients with mild or moderate bronchial asthma were treated with 400mg / d of Urozepine for 14 days. Clinical symptoms and early and late PEFR were recorded. FEV1 was measured before and after treatment. Serum theophylline concentration peak and trough was measured and performed on the 14th day after taking the medicine Statistical analysis. The clinical symptoms and pulmonary function (FEV1, PEFR) were significantly improved after treatment (P <0.001). The plasma theophylline concentration was 5.24 ~ 11.87 μg / ml. It shows that asthma patients with moderate or mild asthma exacerbated oral administration of asthma 400mg / d, up to a low and stable plasma concentration range, good clinical effect, with little gastrointestinal tract irritation, basically no toxic side effects. The authors believe that asthma is a safe and effective anti-asthma drugs.